# To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

> **NCT00226512** · PHASE3 · WITHDRAWN · sponsor: **Hadassah Medical Organization** · enrollment: 203 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Campath-1H /ATG

## Key facts

- **NCT ID:** NCT00226512
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 203 (ESTIMATED)
- **Why stopped:** the PI is no longer work at Hadassah
- **Last updated:** 2011-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226512, "To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00226512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*